论文部分内容阅读
肺动脉高压(PAH)是一类严重威胁人民身体健康的肺血管疾病。上世纪由于阿米雷司、芬氟拉明减肥药及毒性菜籽油引起多起PAH的流行,从而引起各国医学界的高度重视。至今WHO也先后召开3次PAH专家工作组会议讨论PAH的对策,并分别于1998年、2003年先后两次制定PAH的诊断分类标准等,推动了PAH的基础及临床研究的迅速进展。 导报就PAH与相关学科需要共同关注的话题,邀请了心内科专家与相关学科专家进行对话,引起了不小的反响。在刚刚结束不久的第15届长城国际心脏病学会议期间,首次举办了肺血管疾病论坛,并邀请了多位国内外PAH领域的知名专家参加。 美国肺动脉高压协会副主席、Mayo Clinic医学中心教授Dr Michael D.Mcgoon,德国先灵公司高级医学总监Dr Ulrich Madeja,协和医院风湿免疫科曾小峰教授及阜外医院荆志成教授等专家就PAH研究领域的最新进展进行对话,阜外医院徐希奇医生将对话内容整理如下。
Pulmonary hypertension (PAH) is a type of pulmonary vascular disease that is a serious threat to people’s health. In the last century, the epidemic of PAH caused by amiloride, fenfluramine diet pills and toxic rapeseed oil has aroused great attention of medical circles in various countries. To date, WHO has also convened three PAH expert working groups to discuss the PAH countermeasures. In 1998 and 2003 respectively, two diagnostic classification criteria for PAH were formulated, which promoted the rapid progress of basic and clinical research of PAH. Herald on PAH and related disciplines need to focus on topics, invited experts in cardiac medicine and related disciplines to engage in dialogue, has caused no small reaction. The Forum on Pulmonary Vascular Diseases was first held during the 15th Great Wall International Cardiology Conference which was just concluded. A number of well-known experts in PAH field at home and abroad were invited to attend. Dr Michael D. McGoon, Vice Chairman of the American Society of Pulmonary Hypertension, Dr Michael D. Mcgoon, Mayo Clinic Medical Center, Dr Ulrich Madeja, Senior Medical Director of Schering AG of Germany, Professor Zeng Xiaofeng of Rheumatology and Immunology Department of Peking Union Medical College and Professor Jing Zhicheng of Fuwai Hospital, The latest progress of the dialogue, Dr. Xu Xichu Fu Wai Hospital will be the contents of the dialogue as follows.